Back to search results

Observational Study of Lisocabtagene Maraleucel for Mantle Cell Lymphoma

This study is looking at the long-term safety and how well lisocabtagene maraleucel (liso-cel) works for people with Mantle Cell Lymphoma (MCL) that has come back or not responded to previous treatments. Lisocabtagene maraleucel is a type of CAR T-cell therapy. You can join this study if you are 18 or older and have already received at least one infusion of lisocabtagene maraleucel for MCL, following the approved guidelines. The main goal is to track any side effects over a long period, up to 15 years. This study is currently observational, meaning researchers are watching what happens to people who have already received the treatment, rather than giving new treatment. The study aims to include about 300 participants, but its current status is unclear.

Study design
This is an observational study, meaning researchers are collecting information from people who have already received treatment. It aims to include about 300 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for adverse events (side effects) for up to 15 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06788652

A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting

Recruiting
Not specifiedAges 18+Observational
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
~300 participants
Updated 2025-02-24 on ClinicalTrials.gov
What's tested:Lisocabtagene maraleucel

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adverse events (AEs)
Measured over Up to 15 years

Conditions

Mantle Cell Lymphoma (MCL)

Explore related trials

Mantle Cell Lymphoma

NCT06788652

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Center for International Blood and Marrow Transplant Research (CIBMTR)

    Milwaukee, Wisconsinno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb

Who to contact

BMS Study Connect Contact Center www.BMSStudyConnect.com
[email protected]
855-907-3286
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Participants known to be participating in investigational studies at the time of liso-cel infusion.
Participants treated with non-conforming CAR T-cell product.

What this trial measures

  • Adverse events (AEs)Up to 15 years